Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07203001 · ClinicalTrials.gov registry record · Phase 2
A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease
A Phase 2 study of Still´s Disease, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 20
- Study locations
NCT07203001 is a Phase 2 study of Still´s Disease that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 20 participants. The trial reports 20 study locations across 11 states.
The verdict
NCT07203001, a Phase 2 study of Still´s Disease, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study is a phase II trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 in pediatric and adult participants with Still's disease
Conditions Studied
Interventions
- DRUG MAS825
Study Locations (20)
Other
- Novartis Investigative Site - Bordeaux
- Novartis Investigative Site - Le Kremlin-Bicêtre
- Novartis Investigative Site - Lille
- Novartis Investigative Site - Paris
- Novartis Investigative Site - Paris
- Novartis Investigative Site - Münster
- Novartis Investigative Site - Utrecht
- Novartis Investigative Site - Madrid
- Novartis Investigative Site - Valencia
Quebec
- Novartis Investigative Site - Montreal
- Novartis Investigative Site - Montreal
Ohio
- Cincinnati Childrens Hospital - Cincinnati
Oregon
- Legacy Emanuel Research Hosp Portland - Portland
North Rhine-Westphalia
- Novartis Investigative Site - Sankt Augustin
FI
- Novartis Investigative Site - Florence
GE
- Novartis Investigative Site - Genova
RM
- Novartis Investigative Site - Roma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-11-03 |
| Est. Completion | 2029-05-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07203001
The ClinicalTrials.gov registry entry for NCT07203001 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Still´s Disease appearing as the primary indexed condition, and to 1 intervention - of which MAS825 is the first listed.
NCT07203001 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, Quebec, Ohio.
Frequently Asked Questions
What is clinical trial NCT07203001 about?
NCT07203001 is a clinical study titled "A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease". The study is a phase II trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 in pediatric and adult participants with Still's disease
What is the current status of trial NCT07203001?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2025-11-03. Estimated completion is 2029-05-24.
What conditions does trial NCT07203001 study?
This clinical trial studies the following conditions: Still´s Disease.
What interventions are being tested in trial NCT07203001?
The interventions under investigation include: MAS825 (DRUG).
Who is sponsoring clinical trial NCT07203001?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07203001 being conducted?
This trial has 20 study locations across Ohio, Oregon, Quebec, North Rhine-Westphalia, FI. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.